How cells that stop dividing can influence organ scarring

Since the previous research note · Earlier expectation not tested

Track continuity

Since the previous research note: How aging cells and the lung’s scaffold can prolong repair

Previous expectation: Interrupting persistent senescent-cell signaling and damaging repair feedback might preserve lung function while retaining useful tissue repair.

What this study adds: The July 2025 review broadens the discussion to lung, liver and kidney fibrosis and connects intervention strategies with cellular mapping and tissue-model technologies. It does not itself test the earlier forecast of preserved lung function.

---

What changed in this study

Fibrosis begins as a response to persistent injury but can become a lasting pathological state. As scar-forming material builds up, tissue is remodeled, organs lose flexibility or structure, and function can decline. A review published on July 18, 2025, examines how cellular senescence may help sustain this process across lung, liver, and kidney disease. It also compares strategies aimed at senescent cells with newer ways to study the tissue neighborhoods in which fibrosis develops.

The central challenge is not simply finding cells associated with scarring. Researchers must determine which cells are driving harmful signals, which responses are temporary, and how an intervention might affect the tissue’s ability to repair itself.

When a stalled cell changes its neighborhood

Cellular senescence describes a state in which a cell has stopped dividing. The cell remains metabolically active, however, and can release a collection of signaling molecules known as the senescence-associated secretory phenotype, or SASP. In ordinary language, these secretions act like messages sent into the surrounding tissue.

Some of those messages can encourage nearby fibroblasts to become myofibroblasts, cells associated with the production and accumulation of extracellular matrix such as collagen. Signals including TGF-β, IL-6, VEGF, and CCL2 can also alter the behavior of neighboring cells and sustain inflammation. In a damaged lung, for example, senescent alveolar epithelial cells may affect the repair and regeneration of nearby alveolar cells while activating pathways linked to fibroblast activity.

The relationship can run in both directions. A fibrotic tissue environment can bring microcirculation problems, local oxygen shortage, and increased reactive oxygen species. Those stresses can promote further senescence, creating a local feedback loop in which altered cells help maintain the conditions that keep scarring active.

Related patterns appear in other organs, although the same mechanism does not automatically mean the same treatment will work everywhere. In liver disease, senescent hepatocytes and cholangiocytes can influence macrophages, stellate cells, and neighboring cells through secreted factors. In kidney disease, signals such as IL-8 are discussed in connection with prolonged tubular inflammation, myofibroblast activation, and progressive accumulation of extracellular matrix.

Two ways researchers might interrupt the cycle

The review separates two broad therapeutic ideas. Senolytic drugs aim to remove selected senescent cells. Other approaches aim to reduce the harmful secretions released by those cells or block pathways involved in producing them. The distinction matters because removing a cell and changing what it communicates to its neighbors are different interventions with different risks.

Dasatinib plus quercetin provides a concrete example of the first approach. In a mouse model of idiopathic pulmonary fibrosis, the combination improved lung compliance, according to studies summarized by the review. Other studies discussed in the paper found effects on senescent fibroblasts or SASP factors in experimental settings. These findings make senescent cells plausible intervention targets, but they remain tied to the models and studies in which they were observed.

The review also describes strategies that influence signaling rather than relying only on cell removal. Compounds such as procyanidin C1 and astaxanthin are discussed in relation to ROS-dependent mitochondrial signaling in alveolar type II cells. Metformin is discussed in renal fibrosis, including effects on pathways associated with inflammation. These examples show how wide the experimental field is: some candidates are intended to eliminate cells, while others seek to change the molecular environment around them.

A result in a mouse lung model, a change in a cultured cell population, and a response in a patient are not interchangeable forms of evidence. Early human work discussed by the review is more limited than the body of preclinical research, so an encouraging signal does not by itself identify a preferred regimen or establish durable preservation of organ function.

Selectivity is part of the treatment problem

Senescent cells are not a single uniform population, and drugs that affect them may also affect healthy cells or unrelated biological pathways. The review notes that Bcl-2 inhibitors such as ABT-263 and ABT-737 can cause problems involving blood-cell counts and off-target effects. A treatment that reaches several core pathways may also disturb normal physiological processes.

Natural compounds create a different set of practical problems. Quercetin and related flavonoids may have low bioavailability, complex pharmacokinetics, and variable effects between individuals. Differences in how people distribute, metabolize, and clear a drug could increase the risk of accumulation or interactions.

There is also a biological tradeoff. Clearing too many cells, or clearing the wrong population, could weaken tissue repair or provoke unwanted inflammation. For that reason, the question is not simply whether senescent cells can be reduced. It is whether the harmful population, timing, dose, and tissue context can be identified with enough precision to avoid disrupting useful repair.

The review emphasizes that much of the current evidence comes from preclinical models or small, short human studies. Larger clinical studies with long-term follow-up are needed to assess safety, individual efficacy, and whether changes in cellular signals translate into meaningful outcomes for people with fibrosis.

New tools for seeing the fibrotic neighborhood

The research technologies described in the review address a basic limitation of older experiments: a tissue may contain many cell types with different roles, and averaging them together can conceal the populations that matter most.

Single-cell sequencing measures gene activity one cell at a time. This can reveal distinct fibroblast, epithelial, immune, or progenitor populations and show how their states differ during fibrosis or aging. The review cites studies using single-cell and single-nucleus methods to identify aging-associated fibroblast populations and altered gene expression in fibrotic lung tissue.

Spatial transcriptomics adds location. Instead of only asking which genes are active, researchers can ask where the relevant cells sit and which other cells surround them. In idiopathic pulmonary fibrosis, combined spatial and single-cell analyses have been used to examine changes in fibroblasts and alveolar macrophages and to study the organization of the fibrotic niche, where TGF-β signaling is prominent.

These methods are primarily observational. They can sharpen the search for biomarkers and targets by preserving cellular identity and neighborhood, but a pattern in a tissue section does not automatically prove that changing the pattern will improve a patient’s disease. It provides a more detailed starting point for testing cause and effect.

From cell maps to living test systems

Organoids and organ-on-a-chip systems extend that investigation by allowing researchers to study interactions in three-dimensional or controlled environments. Organoids are structures grown from human cells that can reproduce selected features of an organ. They offer more cellular and structural complexity than a flat cell culture, while remaining more experimentally accessible than a whole person.

The review describes fibroblast-dependent alveolar organoids in which epithelial cells and fibroblasts can be studied together. These models have been used to examine senescence in alveolar type II cells, an abnormal intermediate epithelial state, fibroblast activation, organoid contraction, and extracellular-matrix accumulation. Researchers also screened ALK5 inhibitors in this setting. In another reported application, inhibiting HIF2 in lung organoids promoted differentiation of epithelial progenitor cells toward alveolar type II cells, providing a way to investigate repair-related behavior in a controlled model.

Organ-on-a-chip systems add microfluidic control and dynamic physical conditions. A pulmonary fibrosis organoid chip has been used to simulate progressive tissue stiffness and contraction while evaluating the experimental effects of antifibrotic drugs such as pirfenidone and nintedanib. The value of this type of system is not that it reproduces every feature of a patient’s organ. It allows researchers to observe how cells, matrix, movement, and treatment exposure interact over time.

Together, cell-resolved measurements, spatial information, organoids, and chips create a longer chain from observation to experiment. A suspicious cell population can be located, its neighbors can be examined, and a candidate intervention can be tested in a human-derived tissue model before researchers ask whether it merits broader clinical study. Even so, model behavior still needs to be connected to patient outcomes through careful clinical validation.

What this could mean for preserving organ function

For people with fibrotic lung, liver, or kidney disease, the potential benefit is a treatment strategy tailored to the cells and tissue responses that are actually sustaining scarring. If research models identify clinically relevant targets and interventions later demonstrate durable benefit with acceptable safety in patients, slowing further fibrosis could help preserve functioning tissue for longer.

That July 2025 prospect is conditional. The review does not establish that senescent-cell targeting preserves organ function in patients, and it does not show that established scars can be removed. Its contribution is to connect a biological explanation with intervention choices and research systems that may make those choices more precise. For patients, the hoped-for consequence is slower progression and more preserved organ function, not a promise that existing scars can be erased.

Key Sources

• Primary source: Tissue Fibrosis Decoded via Cellular Senescence: Mechanisms, Treatments, and Emerging Technologies.
  DOI or Journal Page · Review or Meta-Analysis · 2025-07-18